Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Perioperative Versus Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Trial (NeoFOL-R Trial)

NCT05529940 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT05529940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05529940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Perioperative Versus Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Trial (NeoFOL-R Trial)
Lead sponsor
Seoul National University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
April 1, 2023
Completion date
December 31, 2027
Enrollment
609 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

effects of chemotherapy, neoadjuvant chemotherapy, resectable pancreatic cancer